Notizie AIOM – anno XV – Pagina 60

29 Maggio 2017

External quality assessment for EGFR mutations in Italy: improvements in performances over the time

External quality assessment (EQA) schemes are essential procedures to assess the quality level of laboratories performing molecular testing of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer. The Italian Association of Medical Oncology (AIOM) ...
Leggi tutto

29 Maggio 2017

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating ...
Leggi tutto

29 Maggio 2017

26 maggio 2017 – Comunicazione e condivisione della ricerca: le nuove tecnologie e il valore fondante dell’etica

29 Maggio 2017

26 maggio 2017 – Procedure di applicazione Managed Entry Agreement – medicinali Vemurafenib L.648/96 e Vemurafenib in associazione a Cobimetinib

29 Maggio 2017

26 maggio 2017 – Attivazione del Registro Vemurafenib in associazione a Cobimetinib

29 Maggio 2017

FDA Grants Nivolumab Priority Review for Liver Cancer

May 25, 2017 - The FDA has granted a priority review designation to nivolumab for use as a treatment for patients with hepatocellular carcinoma (HCC) following prior sorafenib, according to Bristol-Myers Squibb, the manufacturer of the PD-1 inhibitor. The supplemental Biologics ...
Leggi tutto

29 Maggio 2017

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer

This randomized, double-blind, multicenter study aimed to determine the dose of naldemedine, a peripherally-acting µ-opioid receptor antagonist, for future trials by comparing the efficacy and safety of three doses of naldemedine versus placebo in patients with cancer ...
Leggi tutto

25 Maggio 2017

ASCO and Other Oncology, Medical Societies Speak Out Against White House’s Proposed Budget Cuts

May 24, 2017 - On May 23, President Trump presented the White House’s fiscal year 2018 budget request, which proposes a $7.18 billion cut to the National Institutes of Health (NIH)-a budget decrease of 21%. In addition, it cuts the Center for Disease Control and Prevention’s ...
Leggi tutto

25 Maggio 2017

FDA OCE Launches Drug Information Soundcast in Clinical Oncology (DISCO)

May 23, 2017 - The FDA Drug Information Soundcast in Clinical Oncology (DISCO) is a new podcast series from the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), covering new product approvals, emerging safety information for cancer treatments, ...
Leggi tutto

25 Maggio 2017

FDA approves first cancer treatment for any solid tumor with a specific genetic feature

May 23, 2017 - The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather ...
Leggi tutto

LAVORIAMO CON

News

LA PREVENZIONE DEL MELANOMA: AL VIA UNA CAMPAGNA NEI COOP.FI

TUMORI: “AIFA APPROVA LA FORMULAZIONE SOTTOCUTANEA E TRE NUOVE INDICAZIONI TERAPEUTICHE DI NIVOLUMAB”

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

Notizie AIOM – anno XV

External quality assessment for EGFR mutations in Italy: improvements in performances over the time

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

26 maggio 2017 – Comunicazione e condivisione della ricerca: le nuove tecnologie e il valore fondante dell’etica

26 maggio 2017 – Procedure di applicazione Managed Entry Agreement – medicinali Vemurafenib L.648/96 e Vemurafenib in associazione a Cobimetinib

26 maggio 2017 – Attivazione del Registro Vemurafenib in associazione a Cobimetinib

FDA Grants Nivolumab Priority Review for Liver Cancer

Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer

ASCO and Other Oncology, Medical Societies Speak Out Against White House’s Proposed Budget Cuts

FDA OCE Launches Drug Information Soundcast in Clinical Oncology (DISCO)

FDA approves first cancer treatment for any solid tumor with a specific genetic feature